U.S. Perfume Import Readiness Under MoCRA: A Buyer Checklist

Imported cosmetics must comply with the same U.S. laws and regulations that apply to domestically produced cosmetics. For a China-made perfume, that means more than arranging customs entry and obtaining an SDS.

The Modernization of Cosmetics Regulation Act of 2022, or MoCRA, added requirements and FDA authorities involving facility registration, cosmetic product listing, safety substantiation and serious adverse event reporting. The brand, label company, foreign manufacturing facility and U.S. importer need to know which role each one performs.

This article is a planning checklist, not legal advice. Confirm the exact formula, claims, business roles and current FDA requirements with qualified U.S. regulatory and customs professionals.

Quick answer

Before launching an imported perfume in the United States, establish:

whether the product is regulated solely as a cosmetic or also as a drug;
which company is the U.S. “responsible person” under MoCRA;
which foreign facilities manufacture or process the product;
whether facility registration and product listing are required, current and correctly maintained;
how the responsible person substantiates and documents product safety;
whether the final label and claims comply;
how complaints and serious adverse events are received and handled; and
how batch, import and dangerous-goods records connect to the marketed SKU.

FDA states clearly that cosmetic facility registration and product listing are neither an approval program nor promotional tools. FDA does not issue certificates for those registrations or listings.

Official reference: FDA—Registration & Listing of Cosmetic Product Facilities and Products.

1. Confirm that the perfume remains a cosmetic

A conventional fine fragrance applied to the body generally fits within the cosmetic category. Claims can change the regulatory position.

Marketing a product as treating or preventing disease, or as affecting the structure or function of the body, may make it a drug under U.S. law. Product name, website copy, advertising, social posts and distributor materials can all influence the intended-use analysis.

Before manufacturing packaging, review claims such as:

medical or therapeutic effects;
treatment of anxiety, insomnia or another condition;
antimicrobial protection;
changes to body function; or
other physiological outcomes.

Describe scent, style and consumer experience without making unsupported or drug-like claims. If the positioning is uncertain, obtain qualified U.S. review.

Official reference: FDA—Cosmetics Labeling Claims.

2. Identify the MoCRA responsible person

The U.S. definition is not the same as the EU Responsible Person concept.

Under MoCRA, the responsible person is the manufacturer, packer or distributor whose name appears on the cosmetic product label in accordance with the cited U.S. labeling laws. The responsible person has obligations that include cosmetic product listing, safety-substantiation records and serious adverse event reporting.

Document:

legal entity and address;
exact label wording, such as manufacturer or distributor relationship;
authorized regulatory contacts;
Cosmetics Direct or submission-agent access;
safety-file ownership and access;
complaint intake and escalation process;
product-listing maintenance; and
recall and authority-response responsibilities.

Do not assume that the customs importer, brand owner and responsible person are always the same entity. They may be, but the role map should be explicit.

3. Verify foreign facility registration

FDA states that manufacturers and processors subject to MoCRA must register their facilities and renew registration every two years. FDA also describes content updates following changes. For foreign facilities, the Cosmetics Direct process includes U.S. agent information.

For a China perfume supply chain, first identify the actual sites that perform:

fragrance or bulk preparation where relevant to the facility analysis;
blending and maturation;
filling;
packaging or repackaging; and
other manufacturing or processing activities.

Then ask the regulatory professional and facility to determine which sites are required to register. A trading company address is not a substitute for the actual manufacturing-site information.

Request:

facility legal name and physical address;
FDA Establishment Identifier information where applicable;
registration details and current status;
latest renewal or update date;
U.S. agent details for a foreign facility;
operations covered; and
a commitment to report changes that affect the product listing or supply.

Do not advertise the factory as “FDA approved” because it has a registration. FDA expressly says it does not issue cosmetic facility-registration or product-listing certificates.

4. Plan cosmetic product listing

FDA states that a responsible person must list each marketed cosmetic product, including product ingredients, and provide updates annually. The listing connects the product to relevant facilities and responsible-person information.

Prepare the data before launch:

responsible-person legal information;
product name and category;
ingredient information in the required submission format;
applicable manufacturing or processing facilities;
submission contact or authorized agent; and
internal product and listing identifiers.

Several fragrances may be eligible for grouping or require separate treatment depending on the applicable listing rules and formulation differences. Use FDA's current guidance and submission tools rather than assuming that one collection equals one listing.

Set calendar ownership for:

initial listing timing;
annual updates;
product discontinuation or relisting;
formula or facility changes; and
facility biennial renewal.

The official FDA page and its linked final guidance should be checked at the time of submission because portal instructions can change.

5. Evaluate exemptions carefully

MoCRA includes certain small-business exemptions from facility registration and product listing, with exceptions for specified product categories. Other exemptions can apply to facilities or products subject to drug and device requirements.

Do not rely on a supplier's statement that “small orders are exempt.” Order quantity is not the same as the legal exemption analysis. Company sales, affiliates, product type and activities can matter.

Use FDA's current decision tools and qualified counsel to document whether an exemption applies to each responsible person and facility. Even when a registration or listing exemption applies, general duties concerning safe, properly labeled, non-adulterated and non-misbranded cosmetics do not disappear.

6. Build adequate safety-substantiation records

FDA explains that MoCRA requires the responsible person to ensure—and maintain records supporting—that a cosmetic product has adequate substantiation of safety.

The U.S. system does not convert an IFRA certificate, COA or factory test into automatic FDA safety approval. The responsible person needs a reasoned evidence file for the finished product.

Depending on the exact product, relevant information may include:

complete qualitative and quantitative formula available to qualified reviewers;
ingredient and toxicological information;
exact fragrance-compound code and dosage;
IFRA conformity information for intended use;
supplier specifications and batch evidence;
finished-product stability and packaging compatibility;
relevant microbiological rationale or testing;
exposure and intended-use information;
label directions and warnings;
complaint or adverse-event information; and
an expert safety conclusion based on appropriate evidence.

FDA notes that it does not prescribe one universal testing regimen for cosmetics. The evidence should be appropriate to the actual product and support a conclusion by qualified experts.

Official references:

For the roles of common supplier documents, see IFRA, SDS and COA for Perfume.

7. Approve U.S. labeling and claims

The final label should be reviewed against the FD&C Act, Fair Packaging and Labeling Act and applicable regulations. A perfume-label checklist should address:

product identity;
net quantity of contents;
name and place of business;
appropriate relationship wording if the named company is not the manufacturer;
ingredient declaration;
required warnings, if any;
prominence, placement and type-size rules;
country-of-origin marking and customs requirements;
lot or batch traceability as part of the brand's quality system; and
domestic address, domestic phone number or electronic contact information through which the responsible person can receive adverse event reports.

FDA permits fragrance ingredients to be declared in the manner allowed by applicable U.S. labeling rules, but the responsible person's safety reviewer still needs enough confidential composition information to substantiate safety. Consumer label disclosure and safety-file access are different questions.

Color additives require separate attention. FDA does not pre-approve cosmetic products or ingredients generally, with the important exception of certain color additives and their applicable requirements.

Official reference: FDA—Cosmetics Labeling Guide.

8. Create a serious-adverse-event process before launch

The responsible person must be able to receive, assess, document and escalate consumer reports.

FDA states that a responsible person must report serious adverse events associated with use of a cosmetic product in the United States within 15 business days. A copy of the retail-package label is included, and specified new medical or other information received within one year of the initial report must also be submitted within 15 business days.

Operationally, establish:

monitored label contact channel;
intake form and trained staff;
date-of-receipt tracking;
medical and regulatory escalation;
product, batch and distribution traceability;
label-copy archive;
reporting responsibility and backup;
record retention; and
investigation, corrective action and recall decision procedures.

Official reference: FDA—Serious Adverse Event Reporting for Cosmetic Products.

9. Keep import entry and dangerous-goods shipping in the project

MoCRA submissions do not replace customs entry or transport compliance.

Align the manufacturer, exporter, customs broker, importer and dangerous-goods provider on:

manufacturer name and address;
product description and tariff classification;
country of origin;
commercial invoice and packing list;
current SDS and actual transport classification;
carrier-accepted packaging and declarations where required;
shipment quantity and mode; and
records linking the imported lot to the product listing and responsible person.

FDA's import review can request accurate manufacturer and product information. Do not present a trading company as the manufacturer if it did not perform that function.

China manufacturer document request

Ask the production party to provide or support:

legal manufacturer and facility details;
U.S. agent coordination where required;
formula and ingredient information for responsible-person submissions and safety review;
fragrance supplier evidence;
finished-product specification;
stability and compatibility information;
manufacturing and batch records;
COA or agreed quality-release records;
current SDS for the actual product stage and shipment;
label ingredient support;
change notifications; and
complaint and investigation cooperation.

Confidential fragrance information can be transferred to the responsible person's qualified reviewer under agreed controls when direct brand disclosure is restricted. The required regulatory party must still receive sufficient information.

ScentOEM can coordinate these requests across China-based suppliers and the buyer's U.S. professionals. It is not automatically the MoCRA responsible person, U.S. agent, importer of record or legal adviser.

Common mistakes

Calling registration “FDA approval”

FDA explicitly says facility registration and product listing are not cosmetic approval programs and that it does not issue certificates for them.

Confusing the U.S. and EU Responsible Person roles

The terms sound similar but arise from different laws and definitions. Map roles separately for each market.

Listing the product but keeping no safety file

Product listing and adequate safety substantiation are separate obligations.

Using an inactive brand email for adverse events

The label contact must feed an operational intake and escalation process capable of meeting reporting timelines.

Allowing claims to turn perfume into a drug

Review the label and all marketing channels for intended-use claims before launch.

Frequently asked questions

Does FDA approve imported perfume before sale?

FDA does not generally pre-approve cosmetic products, except for specific requirements affecting certain color additives. Firms remain responsible for safe, properly labeled products.

Does a China perfume factory need FDA facility registration?

Manufacturers and processors subject to MoCRA must register; exemptions may apply in defined circumstances. Identify the actual site's activities and use current FDA guidance for the determination.

Who submits the cosmetic product listing?

The MoCRA responsible person must submit or ensure submission of the listing for each marketed cosmetic product, subject to applicable rules and exemptions.

Is an FDA registration certificate available?

No. FDA says it does not issue certificates for cosmetic facility registrations or product listings.

Is an IFRA certificate enough for U.S. safety substantiation?

No. It can support a defined fragrance-use question, but it does not replace a finished-product safety evidence file and qualified conclusion.

Final takeaway

U.S. perfume import readiness begins with roles. Identify the responsible person, the true manufacturing facilities and the importer; then connect facility registration, product listing, safety records, final labeling, adverse-event handling and import documents to the exact SKU.

The purpose is not to collect an “FDA certificate.” It is to build an operating system that can support a safe, traceable, accurately labeled product before and after launch.